Suzanna Lee

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim et al. · Nature Communications · 2020 · 276 citations · Full text

<i>ARID1A</i> alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy

Ryosuke Okamura, Shumei Kato, Suzanna Lee et al. · Journal for ImmunoTherapy of Cancer · 2020 · 182 citations · Full text

High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers

Paul Riviere, Aaron M. Goodman, Ryosuke Okamura et al. · Molecular Cancer Therapeutics · 2020 · 99 citations · Full text

SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer

Gregory P. Botta, Shumei Kato, Hitendra Patel et al. · JCI Insight · 2021 · 66 citations · Full text

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity

Shumei Kato, Ryosuke Okamura, Yuichi Kumaki et al. · OncoImmunology · 2020 · 65 citations · Full text